Comparison of short‐ and long‐term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor therapy

Summary Background The best option between vedolizumab and ustekinumab after anti‐tumour necrosis factor (TNF) failure remains unclear in Crohn's disease. Aims To compare the short‐ and long‐term effectiveness of vedolizumab and ustekinumab in Crohn's disease patients with prior anti‐TNF e...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary Pharmacology & Therapeutics (Suppl) 2021-06, Vol.53 (12), p.1289-1299
Main Authors: Manlay, Luc, Boschetti, Gilles, Pereira, Bruno, Flourié, Bernard, Dapoigny, Michel, Reymond, Maud, Sollelis, Elisa, Gay, Claire, Boube, Mathilde, Buisson, Anthony, Nancey, Stéphane
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized / therapeutic use
Corticosteroids
Crohn Disease / drug therapy
Crohn's disease
Human health and pathology
Hépatology and Gastroenterology
Life Sciences
Pharmaceutical sciences
Phenotypes
Remission
Steroid hormones
Treatment Outcome
Tumor necrosis factor
Tumor Necrosis Factor Inhibitors
Tumor necrosis factor-TNF
Tumors
Ustekinumab / therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background The best option between vedolizumab and ustekinumab after anti‐tumour necrosis factor (TNF) failure remains unclear in Crohn's disease. Aims To compare the short‐ and long‐term effectiveness of vedolizumab and ustekinumab in Crohn's disease patients with prior anti‐TNF exposure. Methods All Crohn's disease patients treated with ustekinumab or vedolizumab after exposure to at least one anti‐TNF agent were included from two referral centres. Primary endpoint was corticosteroid‐free clinical remission defined as Crohn's disease activity index
ISSN:0269-2813
0953-0673
1365-2036
DOI:10.1111/apt.16377